Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 5 Results

Title
Intervention Indication Therapeutic Area Year Actions
Trastuzumab deruxtecan for HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer – second line Trastuzumab deruxtecan (DS-8201a; Enhertu) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Trastuzumab deruxtecan for HER2-positive gastric or gastroesophageal junction adenocarcinoma – third-line Trastuzumab deruxtecan (DS-8201a; Enhertu) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2021 View  |  Download
Trastuzumab deruxtecan for HER2-positive metastatic or unresectable breast cancer Trastuzumab deruxtecan (DS-8201a; Enhertu) Breast cancer Breast Cancer 2019 View  |  Download
Trastuzumab deruxtecan for metastatic HER2 - positive breast cancer – second line Trastuzumab deruxtecan (DS-8201a; Enhertu) Breast cancer Breast Cancer 2020 View  |  Download
Trastuzumab deruxtecan for unresectable or metastatic HER2-low (HR+/-) breast cancer – after chemotherapy Trastuzumab deruxtecan (DS-8201a; Enhertu) Breast cancer Breast Cancer 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications